EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00087191. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy
Study identification
- NCT ID
- NCT00087191
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Advanced Adult Primary Liver Cancer
- Carcinoma of the Appendix
- Fallopian Tube Cancer
- Gastrointestinal Stromal Tumor
- Localized Extrahepatic Bile Duct Cancer
- Localized Gallbladder Cancer
- Localized Gastrointestinal Carcinoid Tumor
- Localized Resectable Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Metastatic Gastrointestinal Carcinoid Tumor
- Ovarian Sarcoma
- Ovarian Stromal Cancer
- Primary Peritoneal Cavity Cancer
- Recurrent Adult Primary Liver Cancer
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Colon Cancer
- Recurrent Extrahepatic Bile Duct Cancer
- Recurrent Gallbladder Cancer
- Recurrent Gastric Cancer
- Recurrent Gastrointestinal Carcinoid Tumor
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Pancreatic Cancer
- Recurrent Rectal Cancer
- Recurrent Small Intestine Cancer
- Recurrent Uterine Sarcoma
- Regional Gastrointestinal Carcinoid Tumor
- Small Intestine Adenocarcinoma
- Small Intestine Leiomyosarcoma
- Small Intestine Lymphoma
- Stage 0 Non-small Cell Lung Cancer
- Stage I Adult Soft Tissue Sarcoma
- Stage I Colon Cancer
- Stage I Gastric Cancer
- Stage I Non-small Cell Lung Cancer
- Stage I Ovarian Epithelial Cancer
- Stage I Ovarian Germ Cell Tumor
- Stage I Pancreatic Cancer
- Stage I Rectal Cancer
- Stage I Uterine Sarcoma
- Stage II Adult Soft Tissue Sarcoma
- Stage II Colon Cancer
- Stage II Gastric Cancer
- Stage II Non-small Cell Lung Cancer
- Stage II Ovarian Epithelial Cancer
- Stage II Ovarian Germ Cell Tumor
- Stage II Pancreatic Cancer
- Stage II Rectal Cancer
- Stage II Uterine Sarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage III Colon Cancer
- Stage III Gastric Cancer
- Stage III Ovarian Epithelial Cancer
- Stage III Ovarian Germ Cell Tumor
- Stage III Pancreatic Cancer
- Stage III Rectal Cancer
- Stage III Uterine Sarcoma
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Adult Soft Tissue Sarcoma
- Stage IV Colon Cancer
- Stage IV Gastric Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Pancreatic Cancer
- Stage IV Rectal Cancer
- Stage IV Uterine Sarcoma
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2004
- Primary completion
- Dec 31, 2005
- Completion
- Not listed
- Last update posted
- Jan 15, 2013
Started 2004
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Abramson Cancer Center of The University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00087191, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2013 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00087191 live on ClinicalTrials.gov.